title: Venoruton®: post thrombotic syndrome. Clinical improvement in venous insufficiency (signs and symptoms) with Venoruton®. A five-year, open-registry, efficacy study.
abstract: OBJECTIVE
  This registry evaluation was conducted in post-thrombotic syndrome (PTS) patients (with a minimum five-year follow up). The study evaluated: 1) variations in peripheral edema with an analogue scoring system; 2) ankle circumference at the PTS limb in comparison with the normal contralateral limb.
  
  
  METHODS
  The difference was expressed in percent increase in circumference measured at the PTS limb; 3) other end-points were observed in a five-year follow-up that created a specific PTS registry. Subjects could follow a management system including: 1) compression; 2) compression and Venoruton® (1 g/day); 3) compression and Venoruton® (2 g/day).
  
  
  RESULTS
  The groups of patients with chronic venous insufficiency (CVI) resulted comparable. The occurrence of a new deep venous thrombosis (DVT) episode was considered a drop out. At five years there were four new DVTs (in 90 patients) in the compression group. There was one case (90 patients included) in the compression and HR (1 g) group and no DVT in group 3. The outcome in groups 2 and 3 was significantly better (0.05) than in group 1. The need for surgery or sclerotherapy (for larger varicose veins), the occurrence of lipodermatosclerosis and ulcerations were significantly lower in the HR groups with a better outcome in the higher dose group (P<0.05). The number of ulcerations were also significantly reduced in the HR groups. The difference in ulcerations was significantly better in the higher dose group in comparison with the other groups (P<0.05). The edema score was significantly reduced at five years in the HR groups (P<0.05) in comparison with the compression group. The higher dose resulted more effective in controlling edema. Both edema score and ankle circumference at five years were significantly lower (P<0.05) in the HR-treated groups with a significant decrease in edema score and ankle circumference in the higher dosage group.
  
  
  CONCLUSIONS
  The study confirms the long-term efficacy of HR in PTS, CVI patients. Controlling signs/symptoms and edema in CVI with HR prevents the most severe complications of CVI including lipodermatosclerosis and venous ulcerations. An early therapeutic program including exercise, risk factor controls, compression an edema-controlling treatment with HR is effective in decreasing the classic complications of PTS syndrome. The important restrictions and difficulties to the use of elastic stockings (in regions with warmer climates) are not applicable to HR that is well tolerated and can be used all the time alone or in association with compression.
authors: Irvine3 Labs, Department of Biomedical Sciences Chieti - Pescara University, Pescara, Italy. edmondo.ippolito@unimi.it
authors: E
authors: E
authors: Ippolito
authors: G
authors: G
authors: Belcaro
authors: M
authors: M
authors: Dugall
authors: M R
authors: MR
authors: Cesarone
authors: B
authors: B
authors: Feragalli
authors: B M
authors: BM
authors: Errichi
authors: G
authors: G
authors: Gizzi
authors: L
authors: L
authors: Pellegrini
authors: A
authors: A
authors: Ledda
authors: R
authors: R
authors: Luzzi
authors: A
authors: A
authors: Ricci
authors: P
authors: P
authors: Bavera
authors: M
authors: M
authors: Hosoi
authors: M
authors: M
authors: Corsi
authors: S
authors: S
authors: Errichi
mesh_terms: D000328:Adult; D000842:Ankle; D003131:Combined Modality Therapy; D004487:Edema / Q000188:drug therapy / Q000628:therapy; D005260:Female; D006801:Humans; D006896:Hydroxyethylrutoside / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D054070:Postthrombotic Syndrome / Q000188:drug therapy* / Q000628:therapy; D012042:Registries; D055502:Secondary Prevention; D053828:Stockings, Compression; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000628:therapy
chemical_list: D006896:Hydroxyethylrutoside; C005865:troxerutin